The National Institute of Health and nonprofits that backed the development of Novartis’ spinal muscular atrophy (SMA) treatment, Zolgensma, could have taken a cue from French organizations to impact the drug’s pricing, the author of a recent opinion piece published on STAT writes.
French nonprofit Généthon, the author writes, attached a pricing condition to its funding contributions.
“Following the appropriate regulatory approvals, Licensee will use Reasonable Efforts to make available within France all the Licensed Products indicated for SMA at prices that would allow appropriate reimbursement scheme and that would not constitute an obstacle for patients to have access to the therapy,” the clause states. “Licensee shall be solely responsible for designing and conducting all Commercialization activities necessary to fulfill its obligations under this Section.”
To read more, click here.